Advertisement

BIOspektrum

, Volume 24, Issue 2, pp 142–145 | Cite as

Shark attack: Haiantikörper für Biomedizin und Biotechnologie

  • Doreen Könning
  • Julius Grzeschik
  • Steffen C. Hinz
  • Simon Krah
  • Martin Empting
  • Harald Kolmar
  • Stefan Zielonka
Wissenschaft Protein Engineering
  • 26 Downloads

Abstract

The adaptive immune system of sharks comprises a very interesting antibody isotype named immunoglobulin new antigen receptor (IgNAR). In contrast to classical antibodies, the antigen binding site of the heavy chain only immunoglobulin is formed by a single variable domain, referred to as vNAR (variable domain of IgNAR). Due to its small size combined with a high stability and selectivity to a cognate antigen, vNAR domains emerged as promising molecules for biotechnological and biomedical applications.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Greenberg AS, Avila D, Hughes M et al. (1995) A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374:168–173CrossRefPubMedGoogle Scholar
  2. [2]
    Feige MJ, Grawert MA, Marcinowski M et al. (2014) The structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulins. Proc Natl Acad Sci USA 111:8155–8160CrossRefPubMedPubMedCentralGoogle Scholar
  3. [3]
    Zielonka S, Empting M, Grzeschik J et al. (2015) Structural insights and biomedical potential of IgNAR scaffolds from sharks. mAbs 7:15–25CrossRefPubMedGoogle Scholar
  4. [4]
    Al Qaraghuli MM, Ferro VA (2017) Analysis of the binding loops configuration and surface adaptation of different crystallized single-domain antibodies in response to various antigens: structural analysis of single domain antibodies. J Mol Recognit 30:e2592CrossRefGoogle Scholar
  5. [5]
    Kovaleva M, Ferguson L, Steven J et al. (2014) Shark variable new antigen receptor biologics–a novel technology platform for therapeutic drug development. Expert Opin Biol Ther 14:1527–1539CrossRefPubMedGoogle Scholar
  6. [6]
    Krah S, Schröter C, Zielonka S et al. (2016) Single-domain antibodies for biomedical applications. Immunopharmacol Immunotoxicol 38:21–28CrossRefPubMedGoogle Scholar
  7. [7]
    Kovaleva M, Johnson K, Steven J et al. (2017) Therapeutic potential of shark anti-ICOSL vNAR domains is exemplified in a murine model of autoimmune non-infectious uveitis. Front Immunol 8 (doi: 10.3389/fimmu.2017.01121)Google Scholar
  8. [8]
    Liu JL, Anderson GP, Delehanty JB et al. (2007) Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library. Mol Immunol 44:1775–1783CrossRefPubMedGoogle Scholar
  9. [9]
    Shao C-Y, Secombes CJ, Porter AJ (2007) Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library. Mol Immunol 44:656–665CrossRefPubMedGoogle Scholar
  10. [10]
    Zielonka S, Weber N, Becker S et al. (2014) Shark attack: high affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation. J Biotechnol 191:236–245CrossRefPubMedGoogle Scholar
  11. [11]
    Könning D, Zielonka S, Grzeschik J et al. (2017) Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol 45:10–16CrossRefPubMedGoogle Scholar
  12. [12]
    Ubah OC, Steven J, Kovaleva M et al. (2017) Novel, antihTNF- a variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development. Front Immunol 8 (doi: 10.3389/fimmu.2017.01780)Google Scholar
  13. [13]
    Könning D, Zielonka S, Sellmann C et al. (2016) Isolation of a pH-sensitive IgNAR variable domain from a yeast-displayed, histidine-doped master library. Mar Biotechnol 18:161–167CrossRefPubMedGoogle Scholar
  14. [14]
    Könning D, Rhiel L, Empting M et al. (2017) Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders. Sci Rep 7:9676CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Doreen Könning
    • 1
  • Julius Grzeschik
    • 2
  • Steffen C. Hinz
    • 2
  • Simon Krah
    • 3
  • Martin Empting
    • 4
  • Harald Kolmar
    • 2
  • Stefan Zielonka
    • 3
  1. 1.Antibody-Drug Conjugates And Targeted Nbe Therapeutics, Merck KgaaDarmstadtGermany
  2. 2.Institut Für Organische Chemie Und BiochemieTu DarmstadtGermany
  3. 3.Protein Engineering And Antibody TechnologiesMerck KGaADarmstadtGermany
  4. 4.Helmholtz-Institut Für Pharmazeutische Forschung SaarlandUniversität SaarlandSaarbrückenGermany

Personalised recommendations